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ABSTRACT
A 29-year-old man suffering from dyspnea and eosinophilic pleural effusion after being on warfarin for pulmonary throm-
boembolism for a period of one month, was readmitted to our hospital. Etiology of pleural effusion other than warfarin was 
excluded. To the best of our knowledge, this is the first case of warfarin-induced pleural effusion reported in Korea. (Korean 
Circ J 2011;41:109-112)
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Introduction
Drug-induced pleural disease is uncommon when com-
pared to drug-induced parenchymal lung disease.
1) Although 
the number of drugs that can cause pleural effusion is increas-
ing, the diagnosis of drug-induced pleural effusion still re-
mains a challenge because of the lack of diagnostic biological 
markers or specific pathological features currently. Eosino-
philic pleural effusion has been reported in association with 
many drugs, including warfarin.
2)3) Although its pathogenesis 
remains unclear, eosinophilic inflammation is the most com-
monly proposed mechanism of warfarin-induced pleural ef-
fusion.
Case
A 29-year-old man was readmitted to our hospital because 
of development of a large right pleural effusion and dyspnea. 
One month before, he had been diagnosed with pulmonary 
thromboembolism of the right main pulmonary artery and 
right middle and lower lobar artery (Fig. 1) and was discharg-
ed on warfarin 5 mg daily as an anticoagulant therapy and, a 
prothrombin time-international normalized ratio (PT-INR) 
was 2.65. He had a past history of atrial fibrillation and Gr-
aves’ disease and there was no history of hypertension, diabe-
tes, allergies, or pulmonary disease. In addition to warfarin, 
his other medications included methimazole, digoxin, furo-
semide, and amiodarone. On current hospital admission, his 
blood pressure was 130/70 mmHg, pulse was irregular and 
pulse rate was 90 beats per minute, respiratory rate was 18 
breaths per minute, and temperature was 36.4°C. On physi-
cal examination, rales were heard in lower lung fields bilat-
erally. However, there was no cardiac murmur or friction rub 
or hepatomegaly or peripheral edema. Chest X-ray demon-
strated a large right pleural effusion (Fig. 2A); there had been 
a history of a small pleural effusion before administration of 
warfarin was started (Fig. 2B). The laboratory findings were 
as follows: hemoglobin level 14.8 g/dL, total leucocyte count 
10,550 cells/mm
2 (58% neutrophils, 28% lymphocytes, and 
6% eosinophils), blood urea nitrogen 9 mg/dL, creatinine 0.9 
mg/dL, aspartate aminotransferase 16 IU/L, alanine amino-
tranferase 16 IU/L, serum sodium 133 mmol/L, serum potas-
sium 3.7 mmol/L, D-dimer >35 μg/mL. The PT-INR was 1.68 
which was lower than the PT-INR at discharge. Prior to the 
current hospital admission, he had visited another hospital 
and was found to have a large right pleural effusion, which 
was suspected to be hemothorax and hence, warfarin was 
discontinued for 3 days. The tests for antinuclear antibodies, 
rheumatoid factor, hepatitis B surface antigen, and anti-hu-
man immunodeficiency virus antibody were negative. Spu-
tum smear was negative for Mycobacterium tuberculosis. 110   Warfarin-Induced Pleural Effusion
Blood and urine cultures were sterile. Cytological analysis of 
pleural fluid obtained at thoracentesis yielded the following 
results: red blood cell count 652 cells/mm
2, white blood cell 
count 2,930 cells/mm
2 (30% neutrophils, 20% lymphocytes, 
26% eosinophils, 4% monocytes, 11% histiocytes), blood glu-
cose level 118 mg/dL, total protein level 5.6 g/dL, albumin 
level 3.0 g/dL, lactate dehydrogenase level 857 IU/L, adenos-
ine deaminase (ADA) level 24 U/L, pH 7.5, and carcinoem-
bryonic antigen (CEA) level 1.57 μg/mL. Pleural fluid Gram 
stain, acid-fast bacilli (AFB) smear and cytology were all neg-
ative. The pathological diagnosis established on pleural biopsy 
was chronic inflammation. The pleural fluid could not be re-
moved completely by thoracentesis, and a chest tube was in-
serted. Warfarin was discontinued prior to chest tube inser-
tion, while the other drugs including amiodarone, digoxin 
and methimazole were continued. After insertion of the chest 
tube, 750 mL of an amber colored pleural fluid was drained 
intially. On the second day, the amount of pleural fluid dr-
ained was 350 mL. 320 mL of pleural fluid was drained on the 
third day, and on the fourth day 280 mL of pleural fluid was 
drained. After discontinuation of warfarin, PT-INR progres-
sively decreased from 1.68 to 1.04 (Fig. 4). As the quantity of 
drained pleural fluid decreased, 2 mg warfarin daily was re-
started as anticoagulant therapy. However, on the following 
day after warfarin administration was restarted, 280 mL of 
pleural fluid was drained on the ninth day and the amount 
of drained pleural fluid did not decrease while the patient was 
on warfarin treatment (Fig. 3). PT-INR was also slightly in-
creased and was in a range between 1.21 and 1.38 (Fig. 4).
After exclusion of the other possible causes of pleural ef-
fusion, warfarin was suspected to have induced the pleural 
Fig. 1. Chest computed tomography showed pulmonary thrombo-
embolism of the right main pulmonary artery and right middle and 
lower lobar artery.
Fig. 2. Chest X-ray demonstrated a large right pleural effusion on current admission (A) and scanty pleural effusion before the warfarin ad-
ministration (B).
A   B  
Fig. 3. The quantity of the drained pleural fluid changed after the administration of warfarin.
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effusion, and after it was discontinued the quantity of pleural 
fluid drained decreased, symptoms resolved, and the chest 
tube was removed 16 days after its insertion. 
Discussion
A large number of drugs are associated with the develop-
ment of pleural inflammation. The presentation of drug-in-
duced pleural disease may vary from an asymptomatic pleu-
ral effusion to acute pleuritis and to symptomatic pleural 
effusion. Except in some cases of drug-induced lupus pleuri-
tis, the pathogenic mechanism for most drug-induced pleu-
ral disease remains speculative. These mechanisms include 
hypersensitivity, allergic reaction, direct toxic effect, increased 
oxygen free radical production, suppression of the antioxi-
dant defense mechanism, and chemical-induced inflamma-
tion.
4)5) Approximately 30 drugs are believed to cause pleural 
disease, and development of pleural fluid eosinophilia has 
been reported in association with therapy with the following 
drugs: dantrolene, nitrofurantoin, fluoxetine, warfarin, glicla-
zide, propylthiouracil, isotrentinoin, mesalamine, bromocrip-
tine, valproic acid, tinazidine, and antibiotics such as peni-
cillin, ceftriaxone, and streptomycin.
2)3) The presence of eosi-
nophilia in pleural fluid may provide a clinical clue to the pres-
ence of drug-induced pleural disease but its presence or ab-
sence is not specific. Pleural fluid eosinophilia is defined as a 
proportion of eosinophils greater than ten percent of total 
nucleated cells in the pleural fluid.
2) Eosinophilia is seen in 
about 5 to 8% of exudative pleural effusions.
6) The important 
causes of pleural fluid eosinophilia include pneumothorax, 
hemothorax, benign asbestos pleural effusion, fungal disease, 
malignancy, pulmonary emboli with pulmonary infarction, 
parasitic infection, connective tissue diseases, and hypersen-
sitivity reaction.
7)8) 
In this case pleural effusion was first considered to have de-
veloped secondary to pulmonary thromboembolism. How-
ever, most pleural effusions associated with pulmonary em-
boli are small, and it is uncommon for the effusion to occupy 
more than one third of the hemithorax.
9) Therefore, pulmo-
nary thromboembolism can be excluded as the cause of pleu-
ral effusion. It was observed that the volume of pleural effu-
sion changed after the use of warfarin. Therefore, warfarin 
was suspected to be the cause of pleural effusion. Warfarin 
therapy might cause a hemothorax,
10) and warfarin-induced 
hemothorax may induce simultaneous pleural fluid and blo-
od eosinophilia, because the presence of red blood cells in the 
pleural space may trigger a cellular reaction.
11) In this case, 
blood eosinophilia was also noted and at 1 month prior to the 
current admission, maximum eosinophilia was 11% (1,142/
mm
3). On admission, blood eosinophil percentage decreased 
to 6% (633/mm
3) and on the fourth day after admission it de-
creased to 5% (394/mm
3), along with a decreased PT-INR and 
improved symptomatology. Although, amiodarone could have 
also been the cause of pleural effusion in this case, warfarin 
was discontinued first while amiodarone was still being con-
tinued, and subsequently there was an improvement in the pa-
tient’s symptoms and a decrease in the quantity of the drained 
pleural fluid. Similarly, after warfarin administration was re-
started, the symptoms aggravated and the quantity of the dr-
ained pleural fluid increased. Thus again, pulmonary throm-
boembolism and amiodarone were excluded as the causes of 
pleural effusion. The possibility of aspiration trauma being a 
cause of the exudative picture could be excluded in view of the 
fact that the pleural fluid was uniformly amber colored and 
was not hemorrhagic in nature. Using the criteria of pleural 
fluid ADA activity of more than 40 IU/L,
12) the possibility of 
tuberculosis pleurisy in this case was low. In addition, the ne-
gative AFB stain and the absence of tuberculous mycobacte-
rial growth in culture were also helpful in excluding pleural 
tuberculosis in this case. 
Malignancy as the cause of pleural effusion was excluded 
since the pleural biopsy and pleural fluid aspiration cytology 
were negative for malignancy, and the pleural fluid CEA level 
was within the normal range.
Fig. 4. The change in PT-INR and dosage of warfarin during admission. PT-INR: prothrombin time-international normalized ratio. 
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After excluding all the possible causes of exudative eosin-
ophilic pleural effusion, warfarin was singled out to be the most 
probable cause of pleural effusion in this case. 
Although there are several reports of drug-induced pleu-
ral effusions, warfarin-induced pleural effusion has not been 
reported in Korea. Warfarin-induced pleural effusion is very 
rare, but consideration of this possibility is important in clini-
cal practice. Whenever a pleural effusion increases in size dur-
ing warfarin use, one should consider this to be a warfarin-
induced side effect.
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